Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAL2771
- Development stage
- Preclinical
- Lead developer
- Nal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
NAL2771 is a transdermal nicotine patch developed by NAL Pharmaceutical Group for smoking cessation. It functions as an agonist of the nicotinic acetylcholine receptor (nAChR), delivering a controlled dose of nicotine to the systemic circulation to alleviate withdrawal symptoms and cravings in individuals attempting to quit smoking. The product is designed as a 1-day patch and is currently in preclinical development.
- Other names
- Nicotine 1-Day PatchNicotine1-Day PatchNicotine-1-Day Patchnicotine
02
Targets
Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on NAL2771.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAL2771.